Bi-Specific MAbS Market Size Forecasted To Achieve $15.19 Billion By 2029 With Steady Growth

The Bi-Specific MAbS Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Bi-Specific MAbS Market Size and Projected Growth Rate?
The market size for bi-specific MAbS has seen swift expansion in the past years. With a rising value from $7.83 billion in 2024 to $9.1 billion in 2025, the compound annual growth rate (CAGR) stands at 16.2%. This growth within the historic period is a result of higher healthcare spending, increased monetary support, and initiatives taken by the government.

The market size for bi-specific MAbS is set to experience fast-paced growth in the upcoming years, with a projection to reach $15.19 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.7%. This growth during the projected period is associated with the escalating incidence of cancer, a growing elderly population, and an upsurge in chronic disease prevalence. Key trends predicted during this period include emphasis on technological improvements, product inventiveness, focus on artificial intelligence, investment in targeted and combination treatment strategies, and the formation of strategic alliances.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3390

What Are the Major Segments in the Bi-Specific MAbS Market?
The bi-specific MAbS market covered in this report is segmented -

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:
1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3
2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3
3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)
4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X
5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET
6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A
7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Are The Driving Bi-Specific MAbS Market Evolution?
The escalating occurrence of cancer and various chronic illnesses is anticipated to fuel the growth of the bispecific monoclonal antibodies market in the coming timeframe. These bispecific monoclonal antibodies are manufactured to treat a range of diseases such as cancer, infectious diseases, disorders of the central nervous system, and autoimmune disorders. These antibodies are deemed to be more potent than monoclonal antibodies because they target multiple tumor antigens on cells to hinder the advancement of cancer. For example, the Cancer Facts & Figures 2023 report from the American Cancer Society (ACS), a voluntary health organization based in the US, projects an estimated 609,820 cancer-related deaths in the USA in 2023. Consequently, an increase in chronic illnesses, including cancer, is expected to surge the requirement for bispecific MAbs for effective treatment of these diseases.

Which Firms Dominate The Bi-Specific MAbS Market Segments?
Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

What Trends Are Expected to Dominate the Bi-Specific MAbS Market in the Next 5 Years?
Firms operating within the bi-specific MAbs market are ramping up their investments in different strategic endeavors including partnerships and collaborations as a means of enlarging their product offerings and increasing their geographical scope. Utilizing strategic collaborations, which are mutually beneficial partnerships between two or more entities aimed at reaching shared targets or objectives, these companies are advancing. An example of this is the exclusive partnership formed in October 2022 between Gilead Sciences and MacroGenics, both US-based biopharmaceutical entities. This partnership was established to develop MGD024, a bispecific antibody that targets CD123 and CD3, leveraging MacroGenics' DART platform, along with two other bispecific research initiatives. As a result of this partnership, Gilead was granted an exclusive option to license MGD024, presenting potential treatment options for different hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024's design aims to limit cytokine-release syndrome (CRS) and encourage intermittent dosing, which could result in more patient-centric treatments and better medical results for those battling AML and MDS.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Is The Largest Region In The Bi-Specific MAbS Market?
North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Bi-Specific MAbS Market?
2. What is the CAGR expected in the Bi-Specific MAbS Market?
3. What Are the Key Innovations Transforming the Bi-Specific MAbS Industry?
4. Which Region Is Leading the Bi-Specific MAbS Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.